Today's Date: June 9, 2023
AHF Applauds President Biden’s Strong Defense of LGBTQ+ Rights   •   IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy   •   TEXAS CAPITAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Texas Capital Bancshares, Inc. on Behalf of Texas Capital   •   Fairmont Mayakoba to host exclusive 2023 pride celebration   •   Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Enc   •   Providing LGBTQI+ people with a safe home in Canada   •   The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Tingo Group, Inc. (TIO) Investor   •   Children's Miracle Network Hospitals® Celebrates 40th Anniversary with Celebrity Friends and Supporters   •   TIO EQUITY ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Tingo Group, Inc. Investors with Losses in Excess of $100K to Secur   •   CGTN: China stresses green development, ethnic unity in modernization drive   •   Sophisticated Utility Vehicle: all-new 2024 Lexus GX Redefines SUV   •   USCIB Releases Pride Month Statement, Supporting Equality and Inclusion   •   Forbes names Sun Life U.S. a Best Employer for Diversity   •   Influencers, Youth Mentorship Organizations and Concerned Citizens Make a Summer Plan to Stop the Violence in Chicago   •   Ventas Realty, Limited Partnership Announces Upsize and Pricing of $750 Million of Exchangeable Senior Notes   •   SoftwareReviews Reveals the Top ESG Software Solutions That Enable Organizations to Build a Culture of Purpose and Sustainabilit   •   Saudi Arabia: Modern means of transportation for easier Hajj   •   A New Era of Three-Row Luxury: The First-Ever Lexus TX   •   ADVANCE AUTO PARTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Advance Auto Parts, Inc. on Behalf of Advance Auto Pa   •   Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI C
Bookmark and Share

Wugen Announces CEO Transition

ST. LOUIS & SAN DIEGO , March 21 /Businesswire/ - Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023. Dr. Srinivasan succeeds Dan Kemp, Ph.D., who has stepped down from his CEO role and the Board of Directors to pursue other opportunities.

“We are delighted to welcome Kumar as Wugen’s next CEO and look forward to leveraging his global leadership, deep expertise in the biopharmaceutical industry, and strong track record of success in company building, corporate strategy, and business development. Under his leadership, the company will be well-positioned to advance our differentiated platform of memory NK and allogeneic CAR-T therapies for patients,” said Natalie Mount, Ph.D., Chair of the Board of Directors at Wugen. “We’d like to thank Dan for his leadership and contributions to the company over the past two years and wish him the best of luck in his future endeavors.”

“I am thrilled to be joining Wugen at this exciting time for the company,” said Dr. Srinivasan. “Wugen has made incredible strides advancing treatments for cancer patients. I look forward to working with Wugen’s talented team as CEO and to continue to execute on our lead clinical-assets, WU-NK-101 and WU-CART-007. Wugen’s memory NK and allogeneic CAR-T cell therapies have the potential to improve patient outcomes by helping to address the needs of patients with solid tumors, acute myeloid leukemia (AML), and T-cell malignancies."

Dr. Srinivasan has over 25 years of experience leading pharmaceutical and biotechnology companies through critical stages of growth, M&A activity, and new product launches. Most recently, he served as executive vice president and chief business officer at Turning Point Therapeutics. Under his leadership, Dr. Srinivasan successfully executed a partnering strategy for reprotrectinib that ultimately led to the acquisition of the company by Bristol Myers Squibb. Before Turning Point Therapeutics, Dr. Srinivasan was vice president and global head of business development for the BioPharmaceuticals business unit at AstraZeneca, where he was instrumental in leading several in-licensing deals that significantly enhanced the strength of the company’s pipeline, established several high priority collaborations, and led all global and regional COVID-19 related business development efforts. Earlier in his career, he held corporate strategy and business development roles at Probiodrug AG, Wyeth Pharmaceuticals, and TorreyPines Therapeutics. Dr. Srinivasan holds an M.B.A. from the University of Chicago, a Ph.D. in organic chemistry from Case Western Reserve University, and a dual B.S./M.S. in chemistry from the University of Madras.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit

STORY TAGS: California, Missouri, Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Finance, Personnel, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News